# US 2024/0390376 A1 · Method for preventing adverse pregnancy outcomes due to use of selective serotonin reuptake inhibitors (ssri) during gestation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390376 A1
- Document ID: US20240390376A1
- Status: Published application
- Kind: A1
- Application number: 18/671,308
- Filed: 2024-05-22
- Published: 2024-11-28
- Earliest claimed: 2023-05-22
- Assignees: Wisconsin Alumni Research Foundation
- Applicants: Wisconsin Alumni Research Foundation
- Inventors: Laura Hernandez; Rafael Reis Domingues; Milo Wiltbank
- Web page: https://patentgrep.com/patent/US20240390376A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/15: Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)}
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 15/06: Antiabortive agents; Labour repressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method to inhibit adverse pregnancy outcomes in a pregnant mammal via administering to the pregnant mammal who is concurrently taking a selective serotonin reuptake inhibitor (SSRI) a therapeutically effective amount of a serotonin receptor antagonist.

## Claims

### Claim 1

A method to inhibit adverse pregnancy outcomes in a pregnant mammal comprising administering to the pregnant mammal a therapeutically effective amount of a serotonin receptor antagonist.

### Claim 2 (depends on 1)

The method of claim 1, wherein the serotonin receptor antagonist is a selective serotonin receptor antagonist.

### Claim 3 (depends on 1)

The method of claim 1, wherein the serotonin receptor antagonist is a 5-HT2A/2C antagonist.

### Claim 4 (depends on 1)

The method of claim 1, wherein the serotonin receptor antagonist is selected from the group consisting of ketanserin, risperidone, trazodone, and nefazodone.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pregnant mammal is a human.

### Claim 6

A method to inhibit adverse pregnancy outcomes in a pregnant mammal comprising administering to a pregnant mammal who is concurrently taking a selective serotonin reuptake inhibitor (SSRI) a therapeutically effective amount of a serotonin receptor antagonist.

### Claim 7 (depends on 6)

The method of claim 6, wherein the SSRI is selected from the group consisting of racemic citalopram, escitalopram (S-citalopram), fluoxetine, fluvoxamine, paroxetine, and sertraline.

### Claim 8 (depends on 6)

The method of claim 6, wherein the serotonin receptor antagonist is a selective serotonin receptor antagonist.

### Claim 9 (depends on 6)

The method of claim 6, wherein the serotonin receptor antagonist is a 5-HT2A/2C antagonist.

### Claim 10 (depends on 6)

The method of claim 6, wherein the serotonin receptor antagonist is selected from the group consisting of ketanserin, risperidone, trazodone, and nefazodone.

### Claim 11 (depends on 6)

The method of claim 6, wherein the pregnant mammal is a human.
